TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
+22.45%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$679M
AUM Growth
+$679M
(+11%)
Cap. Flow
+$110M
Cap. Flow
% of AUM
16.18%
Top 10 Holdings %
Top 10 Hldgs %
61.79%
Holding
30
New
8
Increased
3
Reduced
2
Closed
4
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$58.1M |
| 2 |
Savara
SVRA
|
$37.8M |
| 3 |
Taysha Gene Therapies
TSHA
|
$35.1M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$32.1M |
| 5 |
CMPS
Compass Pathways
CMPS
|
$28.5M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$96.3M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
$52.9M |
| 3 |
Immunovant
IMVT
|
$12.3M |
| 4 |
Aclaris Therapeutics
ACRS
|
$5.49M |
| 5 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$2.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Structure Therapeutics
GPCR
$1.11B
| $75.8M | 11.16% |
1,502,747
+1,152,747
| +329% | +$58.1M |
|
2
Cogent Biosciences
COGT
$1.69B
| $54.9M | 8.08% |
5,631,042
| – | – |
|
3
Geron
GERN
$893M
| $49.6M | 7.3% |
23,375,839
-213,940
| -0.9% | -$454K |
|
4
AN2 Therapeutics
ANTX
$30.1M
| $43.1M | 6.34% |
2,678,209
+1,388,889
| +108% | +$22.3M |
|
|
5
Savara
SVRA
$567M
| $37.8M | 5.57% |
+10,000,000
| New | +$37.8M |
|
|
6
Taysha Gene Therapies
TSHA
$797M
| $35.1M | 5.17% |
+11,111,111
| New | +$35.1M |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $32.7M | 4.81% |
3,395,495
| – | – |
|
|
INBX
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $32.1M | 4.73% |
+1,750,387
| New | +$32.1M |
|
|
JBIO
9
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $29.9M | 4.4% |
2,201,274
| – | – |
|
|
ICVX
10
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $28.7M | 4.23% |
3,703,704
| – | – |
|
|
CMPS
11
Compass Pathways
CMPS
$424M
| $28.5M | 4.2% |
+3,858,000
| New | +$28.5M |
|
12
Ventyx Biosciences
VTYX
$171M
| $28.3M | 4.17% |
815,724
| – | – |
|
13
Tyra Biosciences
TYRA
$675M
| $27.4M | 4.03% |
1,989,103
| – | – |
|
14
Madrigal Pharmaceuticals
MDGL
$9.76B
| $26.3M | 3.87% |
179,917
+30,000
| +20% | +$4.38M |
|
|
SLN
15
Silence Therapeutics
SLN
$227M
| $20.7M | 3.04% |
2,104,875
| – | – |
|
16
Tarsus Pharmaceuticals
TARS
$2.47B
| $20.3M | 2.99% |
+1,142,857
| New | +$20.3M |
|
|
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $19.3M | 2.84% |
+869,908
| New | +$19.3M |
|
18
Dyne Therapeutics
DYN
$1.92B
| $14.8M | 2.18% |
1,650,150
| – | – |
|
|
CNTA
19
Centessa Pharmaceuticals
CNTA
$2.25B
| $13.2M | 1.94% |
+2,040,816
| New | +$13.2M |
|
20
Kura Oncology
KURA
$686M
| $13M | 1.91% |
1,423,642
| – | – |
|
|
21
Immunovant
IMVT
$2.56B
| $12.9M | 1.89% |
334,853
-320,000
| -49% | -$12.3M |
|
22
Entrada Therapeutics
TRDA
$208M
| $9.24M | 1.36% |
584,955
| – | – |
|
|
GRCL
23
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $8.75M | 1.29% |
+3,038,889
| New | +$8.75M |
|
24
Cabaletta Bio
CABA
$133M
| $7.41M | 1.09% |
486,795
| – | – |
|
25
Merus
MRUS
$4.98B
| $7.07M | 1.04% |
300,000
| – | – |
|